ABBVIE INC. (NYSE:ABBV) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition
On January25, 2019, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December31, 2018. A copy of the press release is furnished as Exhibit99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
AbbVie Inc. Exhibit
EX-99.1 2 abbv-20181231xexhibit991.htm EXHIBIT 99.1 Exhibit PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results •Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent•Delivers Full-Year Net Revenues of $32.753 Billion on a GAAP Basis; Adjusted Net Revenues of $32.733 Billion Increased 15.2 Percent on an Operational Basis•Full-Year Global HUMIRA Sales of $19.936 Billion Increased 8.2 Percent on a Reported Basis,…
To view the full exhibit click
About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.